Lexicon's Phase 3 sotagliflozin HCM trial exceeds enrollment target with 542 patients

LXRX•2026-10-23

Lexicon Pharmaceuticals said its Phase 3 SONATA-HCM trial enrolled 542 patients, exceeding its 500-patient target. Baseline data are due October 24, 2026, and topline results are expected in the first quarter of 2027.

Lexicon's Phase 3 sotagliflozin HCM trial exceeds enrollment target with 542 patients

1. Trial enrollment and timing

Related News

Nasdaq trade halt continues; reason not available at 08:40 am

Founder Group regains compliance with Nasdaq minimum publicly held shares requirement

Apple's foldable iPhone hits stores with $2,000 price tag and scarce supply

Fiserv appoints Raj Seshadri to board of directors

LKQ Q3 revenue misses estimates on Europe underperformance